^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    budigalimab (ABBV-181)

    i
    Other names: ABBV-181, ABBV 181, ABBV181
    Company:
    AbbVie
    Drug class:
    PD1 inhibitor
    Related drugs:
    5d
    TTX-030-003: Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov)
    P2, N=194, Completed, Trishula Therapeutics, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2027 --> Mar 2026 | Trial primary completion date: Feb 2027 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • budigalimab (ABBV-181) • eltivutabart (TTX-030)
    11d
    M23-385: Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=288, Active, not recruiting, AbbVie | Trial completion date: Jun 2026 --> Nov 2027 | Trial primary completion date: Jun 2026 --> Nov 2027
    Trial completion date • Trial primary completion date • Adverse events • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    1m
    Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma. (PubMed, J Immunother Cancer)
    The quadruple combination of ABBV-368, tilsotolimod, nab-paclitaxel, and budigalimab was well tolerated and demonstrated pharmacodynamic activity. Several patients had disease stabilization, but clinical responses were limited. Initial priming and T-cell immune activation were inadequate to overcome prior therapy resistance mechanisms including a hypothesized unfavorable tumor microenvironment. Future work investigating strategies to target this inhibitory tumor microenvironment with optimally scheduled immunotherapy combinations in selected patients and indications is urgently needed to improve patient outcomes.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    albumin-bound paclitaxel • budigalimab (ABBV-181) • revdofilimab (ABBV-368) • tilsotolimod (IMO-2125)
    1m
    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (clinicaltrials.gov)
    P1, N=694, Recruiting, AbbVie | N=512 --> 694 | Trial primary completion date: Jul 2026 --> Jul 2027
    Enrollment change • Trial primary completion date • Adverse events • First-in-human
    |
    PD-1 (Programmed cell death 1)
    |
    BRAF V600E • BRAF V600 • HER-2 mutation
    |
    Avastin (bevacizumab) • budigalimab (ABBV-181) • telisotuzumab adizutecan (ABBV-400)
    3ms
    LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=840, Recruiting, AbbVie | Active, not recruiting --> Recruiting | N=167 --> 840
    Enrollment open • Enrollment change • Adverse events
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    4ms
    LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=167, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=840 --> 167
    Enrollment closed • Enrollment change • Adverse events
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    4ms
    A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=163, Active, not recruiting, AbbVie | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    budigalimab (ABBV-181) • giloralimab (ABBV-927)
    4ms
    Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations (clinicaltrials.gov)
    P1/2, N=252, Recruiting, AbbVie | N=132 --> 252
    Enrollment change • Adverse events • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR wild-type
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • telisotuzumab adizutecan (ABBV-400)
    5ms
    A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors (clinicaltrials.gov)
    P1, N=220, Recruiting, AbbVie | Trial completion date: Apr 2029 --> Oct 2030
    Trial completion date • Adverse events • First-in-human
    |
    budigalimab (ABBV-181)
    5ms
    A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors (clinicaltrials.gov)
    P1, N=220, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • First-in-human
    |
    budigalimab (ABBV-181)
    5ms
    Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer. (PubMed, Iran J Pharm Res)
    This review summarizes a range of ADCs targeting tumor-associated antigens in ovarian cancer, including mirvetuximab soravtansine (MIRV), trastuzumab deruxtecan (T-DXd), datopotamab deruxtecan (Dato-DXd), sacituzumab tirumotecan (SKB-264), PF-06664178, anetumab ravtansine (BAY 94-9343), BMS-986148, DMOT4039A, RC88, lifastuzumab vedotin (DNIB0600A), upifitamab rilsodotin (ABBV-181), ZW220, DMUC4064A, and sofituzumab vedotin (DMUC5754A). The ADCs hold significant potential to reshape the treatment landscape for ovarian cancer by providing targeted therapeutic options. Further research is required to optimize patient selection, address resistance mechanisms, and improve safety profiles.
    Review • Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Elahere (mirvetuximab soravtansine-gynx) • budigalimab (ABBV-181) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan) • anetumab ravtansine (BAY 94-9343) • upifitamab rilsodotin (XMT-1536) • RG7600 • lifastuzumab vedotin (DNIB0600A) • RG7882 • ZW220 • BMS-986148
    6ms
    A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors (clinicaltrials.gov)
    P1, N=220, Not yet recruiting, AbbVie
    New P1 trial • Adverse events • First-in-human
    |
    budigalimab (ABBV-181)